Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early...

Descripción completa

Detalles Bibliográficos
Autores: Díaz-González, Álvaro|||0000-0003-3610-2263, Sapena, Victor|||0000-0003-4379-6486, Boix, Loreto|||0000-0002-6015-3901, Torres, Ferran|||0000-0002-7355-7913, Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705, Da Fonseca, Leonardo G.|||0000-0002-0216-3618, Llarch, Neus|||0000-0003-3209-0453, Iserte, Gemma|||0000-0003-3908-8743, Guedes, Cassia, Muñoz-Martínez, S.|||0000-0003-0663-0575, Darnell, Anna, Belmonte, Ernest|||0000-0003-3572-9769, Rimola, Jordi|||0000-0002-1814-4198, Forner, Alejandro|||0000-0002-9014-4950, Ayuso, Carmen|||0000-0002-9606-6957, Bruix, Jordi|||0000-0002-9826-0753, Reig, María|||0000-0002-5711-9534
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:256487
Acceso en línea:https://ddd.uab.cat/record/256487
https://dx.doi.org/urn:doi:10.1002/ueg2.12111
Access Level:acceso abierto
Palabra clave:Diarrhoea
Hepatocellular carcinoma
Resistance
Sorafenib
Survival
Tyrosine kinase inhibitor
Descripción
Sumario:Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?.

Similares en LA Referencia